Get started
Work

MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML

Year: 2011
Type: article
Study design: Observational Study
Abstract: MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.
DOI: 10.1111/j.1365-2141.2011.08662.x
Authors: Yin Xiong, Zejuan Li, Min Ji, Aik‐Choon Tan, Judson Bemis, Jove‐Victor Tse, Gang Huang, Jino Park, Chunyan Ji, Jianjun Chen, Lynne T. Bemis, Kevin D. Bunting, William Tse
Institutions: University of Colorado Cancer Center, University of Colorado Denver, University of Chicago, West Virginia University, Shandong University, West Virginia University Hospitals, Cincinnati Children's Hospital Medical Center, Emory University, John A. Hartford Foundation
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W2037982604
FWCI: 2.64
Cites: 16
Cited by: 37
Related to: 10